Compares two heart rhythm procedures for persistent atrial fibrillation
Compares pulsed field ablation with radiofrequency ablation in adults with persistent atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-lasting (persistent) atrial fibrillation who are about to have their first catheter ablation. It compares two ablation methods.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Non-valvular persistent atrial fibrillation lasting 3 months to 3 years, with left atrial diameter under 50 mm on echocardiogram.
- Earlier treatment
- This must be the first catheter ablation. People with earlier cardiac surgery, a pacemaker, left atrial appendage closure or patent foramen ovale closure cannot join.
Main reasons for not taking part
- Atrial fibrillation from a reversible cause
- LVEF below 30%
- Severe liver or kidney problems, or a history of dialysis
- Pregnancy
- Life expectancy under 1 year
Read by machine on 9 November 2026.
Where in China
- Beijing Anzhen Hospital, Capital Medical UniversityBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Anzhen Hospital
- Trial code
- NCT06791629
- Record updated
- 24 January 2025
- Original description
This clinical trial aims to compare the efficacy and safety of pulsed field ablation and radiofrequency ablation to treat persistent atrial fibrillation in adults.Read full original descriptionShow less
Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation: A Randomized, Open-label, Non-inferior Study
This clinical trial aims to compare the efficacy and safety of pulsed field ablation and radiofrequency ablation to treat persistent atrial fibrillation in adults.
Participants will:
Undergo pulsed field ablation or radiofrequency ablation. Keep follow-up for at least 12 months.
Inclusion: 18-80 years; Patients with non-valvular persistent atrial fibrillation undergoing their first catheter ablation (AF duration: 3 months to 3 years); Left atrial diameter on parasternal long-axis view of echocardiogram < 50 mm; Agree to be randomly assigned to the ablation strategy and able to follow up.
Exclusion: Currently enrolled in another trial evaluating medical devices or drugs; Severe congenital heart disease; History of cardiac surgery, such as coronary artery bypass grafting, mechanical valve or prosthetic valve replacement; History of pacemaker implantation, left atrial appendage closure, or patent foramen ovale closure; Contraindications to right or left heart catheterization; Life expectancy < 1 year (e.g., advanced malignancy, end-stage renal disease); LVEF < 30%; Severe liver or kidney dysfunction (eGFR < 15, Child-Pugh grade 3), or history of dialysis; Atrial fibrillation due to reversible causes; Contraindications to oral anticoagulation; Pregnancy; Other situations where the investigator determines the subject is unsuitable for the study.